When treating bacterial infections, especially in patients whose immune systems are already compromised, time is of the essence. Knowledge of what bacteria have infected the patient, and which antibiotic to prescribe, must come as early as possible. In the best-case scenario, such information would be at a physician's fingertips even before life-threatening symptoms arise in the patient.

Infectech Inc. is doing its part to modernize the detection of infectious bacteria and make such information readily accessible. CEO and co-founder Mitchell Felder, along with chairman and co-founder Robert Ollar, have developed assays designed to rapidly detect and identify infectious bacterial strains as well as determine which antibiotic or combination of antibiotics will curtail bacterial growth.